Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 10, 2013, Pages 1430-1438

  Ross, Duncan ^a   Jones, Monica ^a   Komanduri, Krishna ^a   Levy, Robert B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alkylating agent; Allogeneic hematopoietic stem cell transplantation (HSCT); Graft versus host disease (GVHD); Lymphopenia induced proliferation; Myeloablative conditioning; Post transplantation cyclophosphamide

Indexed keywords

ANTIGEN; CYCLOPHOSPHAMIDE; GLYCOPROTEIN GP 100;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; DONOR; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; T LYMPHOCYTE;

ALKYLATING AGENT; ALLOGENEIC-HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT); GRAFT-VERSUS-HOST DISEASE (GVHD); LYMPHOPENIA-INDUCED PROLIFERATION; MYELOABLATIVE CONDITIONING; POST-TRANSPLANTATION CYCLOPHOSPHAMIDE;

ANIMALS; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84884197707     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.06.019     Document Type: Article

References (57)

1. Thomas E.D., Fefer A. Graft-versus-host disease. NEngl J Med 1979, 301:556.
2. Ueno N.T., Rizzo J.D., Demirer T., et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008, 41:537-545.
3. Epstein R.B., Graham T.C., Buckner C.D., et al. Allogeneic marrow engraftment by cross circulation in lethally irradiated dogs. Blood 1966, 28:692-707.
4. Buckner C.D., Epstein R.B., Rudolph R.H., et al. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970, 35:741-750.
5. Santos G.W., Hess A.D., Vogelsang G.B. Graft-versus-host reactions and disease. Immunol Rev 1985, 88:169-192.
6. Matte C.C., Liu J., Cormier J., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004, 10:987-992.
7. Mielke S., Solomon S.R., Barrett A.J. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 2005, 7:109-115.
8. Sprent J., Miller J.F. Interaction of thymus lymphocytes with histoincompatible cells. I. Quantitation of the proliferative response of thymus cells. Cell Immunol 1972, 3:361-384.
9. Edinger M., Hoffmann P., Contag C.H., Negrin R.S. Evaluation of effector cell fate and function by invivo bioluminescence imaging. Methods 2003, 31:172-179.
10. Beilhack A., Schulz S., Baker J., et al. Invivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005, 106:1113-1122.
11. Godfrey W.R., Krampf M.R., Taylor P.A., Blazar B.R. Exvivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004, 103:1158-1165.
12. Martins S.L.R., John L.S.S., Champlin R.E., et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 2004, 104:3429-3436.
13. Spierings E., Hendriks M., Absi L., et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet 2007, 3:e103.
14. De Bueger M., Bakker A., Van Rood J.J., et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. JImmunol 1992, 149:1788-1794.
15. Strasser A., Harris A.W., Jacks T., Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994, 79:329-339.
16. Zong W.-X., Ditsworth D., Bauer D.E., et al. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18:1272-1282.
17. Owens A.H., Santos G.W. The effect of cytotoxic drugs on graft-versus-host disease in mice. Transplantation 1971, 11:378-382.
18. Glucksberg H., Fefer A. Chemotherapy of established graft-versus-host disease in mice. Transplantation 1972, 13:300-305.
19. Storb R., Buckner C.D., Dillingham L.A., Thomas E.D. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion. Cancer Res 1970, 30:2195-2203.
20. Eto M., Mayumi H., Tomita Y., et al. Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. JExp Med 1990, 171:97-113.
21. Luznik L., Engstrom L.W., Iannone R., Fuchs E.J. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biology of Blood and Marrow Transplantation 2002, 8:131-138.
22. Luznik L., Jones R.J., Fuchs E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010, 17:493-499.
23. Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1835-1844.
24. Luznik L., Bolaños-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
25. Bayraktar U.D., de Lima M., Ciurea S.O. Advances in haploidentical stem cell transplantation. Rev Bras Hematol Hemoter 2011, 33:237-241.
26. Bolaños-Meade J., Fuchs E.J., Luznik L., et al. HLA-haploidentical bone marrow transplantation with post-transplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012, 120:4285-4291.
27. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide: Effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
28. Grosso D., Carabasi M., Filicko-O'Hara J., et al. A2-step approach tomyeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing. Blood 2011, 118:4732-4739.
29. Bell E.B., Sparshott S.M., Drayson M.T., Ford W.L. The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells. JImmunol 1987, 139:1379-1384.
30. Tanchot C., Lemonnier F.A., Perarnau B., et al. Differential requirements for survival and proliferation of CD8 naïve or memory T cells. Science 1997, 276:2057-2062.
31. Schluns K.S., Kieper W.C., Jameson S.C., Lefrançois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells invivo. Nat Immunol 2000, 1:426-432.
32. Goldrath A.W., Sivakumar P.V., Glaccum M., et al. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells. JExp Med 2002, 195:1515-1522.
33. Parkman R. Antigen-specific immunity following hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008, 40:91-93.
34. Bolotin E., Annett G., Parkman R., Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999, 23:783-788.
35. Mackall C.L., Fry T.J., Bare C., et al. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 2001, 97:1491-1497.
36. Alpdogan O., Muriglan S.J., Eng J.M., et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. JClin Invest 2003, 112:1095-1107.
37. Bosch M., Khan F.M., Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012, 19:324-335.
38. Toubert A., Glauzy S., Douay C., Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: Never say never again. Tissue Antigens 2012, 79:83-89.
39. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
40. Baker M.B., Riley R.L., Podack E.R., Levy R.B. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci USA 1997, 94:1366-1371.
41. Gatza E., Rogers C.E., Clouthier S.G., et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory Tcells. Blood 2008, 112:1515-1521.
42. Tan J.T., Dudl E., LeRoy E., et al. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. PNAS 2001, 98:8732-8737.
43. Hwang L.N., Yu Z., Palmer D.C., Restifo N.P. The invivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. Cancer Res 2006, 66:1132-1138.
44. Johnson L.D.S., Jameson S.C. Self-specific CD8+ T cells maintain a semi-naïve state following lymphopenia-induced proliferation. JImmunol 2010, 184:5604-5611.
45. Ross M., Schmidt G.M., Niland J.C., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: Effect on chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant 1999, 5:285-291.
46. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989, 73:1729-1734.
47. Maeda T., Eto M., Nishimura Y., et al. Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. Immunology 1993, 78:113-121.
48. Eto M., Mayumi H., Tomita Y., et al. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. JImmunol 1991, 146:1402-1409.
49. Juchem K.W., Anderson B.E., Zhang C., et al. Arepertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory Tcells. Blood 2011, 118:6209-6219.
50. Magni M., Shammah S., Schiró R., et al. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996, 87:1097-1103.
51. Hess D.A., Meyerrose T.E., Wirthlin L., et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004, 104:1648-1655.
52. Armstrong L., Stojkovic M., Dimmick I., et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004, 22:1142-1151.
53. Mirkes P.E., Ellison A., Little S.A. Role of aldehyde dehydrogenase (ALDH) in the detoxication of cyclophosphamide (CP) in rat embryos. Adv Exp Med Biol 1991, 284:85-95.
54. Cohen J.J., Duke R.C., Fadok V.A., Sellins K.S. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 1992, 10:267-293.
55. Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: Emphasis on use in rheumatic diseases. Semin Arthritis Rheum 1983, 12:359-372.
56. Jones R.J. Haploidentical transplantation: Repurposing cyclophosphamide. Biol Blood Marrow Transplant 2012, 18:1771-1772.
57. Geva-Zatorsky N., Dekel E., Batchelor E., et al. Fourier analysis and systems identification of the p53 feedback loop. PNAS 2010, 107:13550-13555.